Hospital

Tizlelizumab is a unique anti-PD-1 monoclonal antibody that is being analyzed in 14 pivotal clinical trials across an array of solid tumors.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

Students from the University of the Sciences’ Philadelphia College of Pharmacy triumphed.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

Most pharmacy schools don’t teach personal finance, so it’s up to you to set yourself up for success by taking control of your money while you’re still a student.

Nicole Palmer, senior manager of Volunteer Engagement at US Pharmacopeia (USP), and Michelle Then, PharmD, MBA, member of the USP Healthcare Safety and Quality Expert Committee, discuss the benefits of being a volunteer at USP and the opportunities for students and early career pharmacists.

Women in the study had higher rates of urgent procedures and were in poorer health when they received surgery.

How would you handle these patients' questions?

An overview for community pharmacies of a process to minimize vaccine errors using a COVID-19 vaccine point of distribution as an example.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin designed to decrease contractile function and improve VO2 in patients with obstructive hypertrophic cardiomyopathy.

Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Data from the study shows a strong immune response in this age group following this dose, with no new safety signals.

Investigators observe strong immunogenicity profile in study participants aged 5 to 17 years 1 month after the primary vaccination series.

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.

Hogue is the second pharmacist to ever serve on the advisory committee.

Acute graft-versus-host disease (aGVHD) is the most frequently encountered, life- threatening complication following an allogeneic hematopoietic stem cell transplant (aHSCT).

Ravulizumab-cwvz (Ultomiris) is the first and only long-acting C5 complement inhibitor for the treatment of generalized myasthenia gravis to gain FDA approval.

Scemblix is indicated for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors.

Thiazolidinediones may change metabolic patterns and contribute to weight gain.

Individuals with diabetes, a higher body mass index, or a history of hospitalization are more likely to develop the condition, the analysis shows.

Of these visits, approximately 11%, or 8 million, resulted in antibiotic prescriptions, foremost commonly for illnesses that are not caused by a bacterial infection, such as bronchitis, non-bacterial skin conditions, and viral respiratory-tract infections.

Evusheld concentrations remained elevated in serum for 6 months after administration, supporting that a single dose could provide long-term protection against COVID-19.

Almost all the participants who had not had COVID-19 seroconverted after vaccination, meaning they made antibodies against the virus.

Telehealth use expanded in the pharmacy during the pandemic, however, pharmacy personnel face challenges when implementing these services, beginning with regulatory requirements.

The data show that the 10-year survival rate of patients with breast cancer who survived Hurricane Katrina was much lower than those who did not face a major weather event.

Two-thirds of women diagnosed with endometrial cancer have localized disease and a 5-year relative survival of 95%.

Up to 50% of all patients with breast cancer have tumors with a HER2 immunohistochemistry level not currently eligible for HER2-targeted therapy.

Oncologists and rheumatologists reported the highest costs to their practices at $6700 and $7900 per month, respectively.

Of the 53 pediatric patients enrolled in the CARAVAN study, no new safety signals were apparent for patients treated with remdesivir.

STRIDE regimen of a single priming dose added to Imfinzi is the first dual immune checkpoint blockage regimen to improve overall survival in a phase 3 trial in this setting.